设为首页 加入收藏

TOP

Ruconest 2100 U powder for solution for injectionPatient’s L
2014-07-18 13:28:07 来源: 作者: 【 】 浏览:351次 评论:0

For doctors

 

What is it and how is it used?

Ruconest contains conestat alfa as the active substance. Conestat alfa is a recombinant form of human C1 inhibitor ( rhC1INH) and is produced using recombinant DNA technology from the milk of rabbits.

Ruconest is to be used by adults with a rare inherited blood disorder, called Hereditary Angioedema(HAE). These patients have a shortage of the C1 inhibitor protein in their blood. This can lead to repeated attacks of swelling, pain in the abdomen, difficulty breathing and other symptoms.

The administration of conestat alfa (Ruconest) is to resolve the shortage of C1 inhibitor and will lead to reduction of symptoms of an acute attack of HAE.

What do you have to consider before using it?

Do not use Ruconest
- If you are or think you are allergic (hypersensitive) to rabbits
- If you are allergic (hypersensitive) to conestat alfa or any of the other ingredients of the medicinal product (see section 6).

Only use Ruconest if you have a negative test for rabbit allergy (IgE). Repeat this test every year or after every 10 treatments with Ruconest, whichever occurs first.

Take special care with Ruconest
If you experience allergic reactions e.g. hives, rash, itching, dizziness, wheezing, difficulty breathing or your tongue swells up following the administration of Ruconest, you should seek emergency medical assistanceso that symptoms of your allergic reaction can be treated urgently.

Children and adolescents
Ruconest is not indicated for use in children and adolescents under 18 years old.

Using other medicines
Please inform your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
If you are receiving acute treatment for blood clots, you should not be treated with Ruconest at the same time.

Pregnancy and breast-feeding
It is not recommended to use Ruconest during pregnancy or breast-feeding.
If you plan becoming pregnant, discuss with your doctor before starting to use Ruconest.

Driving and using machines
Do not drive or use machinery if you feel dizzy or suffer from headache after using Ruconest.

How is it used?

Ruconest will be given to you directly into a vein over a period of approximately 5 minutes by your doctor or by a nurse. Your dose will be worked out based on your weight.
Most of the time a single dose is sufficient, but a second dose may be needed. No more than 2 doses should be given within 24 hours.

The instructions for use are clearly described in the doctor’s information leaflet and are attached.

What are possible side effects?

Like all medicines, Ruconest can cause side effects, although not everybody gets them.

If your symptoms get worse and/or you develop a rash, tingling, difficulty breathing or your face or tongue swells up, get medical attention immediately.
This may indicate that you have developed an allergy to Ruconest.

Some side effects may occur during treatment with Ruconest:
Common (affect 1 to 10 users in 100):
headache

Uncommon (affect 1 to 10 users in 1,000):
sensation of tingling, prickling or numbness in the skin or limb (paraesthesia), dizziness, throat irritation, abdominal pain, diarrhoea, nausea, hives and swelling of the skin.

If any of the side effects gets serious, or if you notice any side effects not listed in the leaflet, please inform your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.
Do not use this medicine after the expiry date stated on the carton and on the label of the vial after EXP.
The expiry date refers to the last day of that month

Do not store above 25°C.
Store in the original package in order to protect from light.

Before Ruconest can be administered, it needs to be dissolved in water for injections, by a healthcare professional.
Once reconstituted, the product should be used immediately.

↑ back to table of contents ↑

For doctors

What is it?

Ruconest is a powder that is made up into a solution for injection. It contains the active substance conestat alfa.

What is it used for?

Ruconest is used to treat attacks of hereditary angioedema in adults (aged 18 years or over). Patients with angioedema have attacks of swelling that can occur anywhere in the body, such as in the face or limbs, or around the gut, causing discomfort and pain. Ruconest is used in patients with hereditary angioedema that is linked to naturally low levels of a protein called ‘C1 esterase inhibitor’.

The medicine can only be obtained with a prescription.

How is it used?

Treatment with Ruconest should be started under the supervision of a doctor with experience in diagnosing and treating hereditary angioedema. The medicine should only be given by a healthcare professional. Patients who have not received Ruconest before should be tested to see if they have antibodies against rabbit dander (shed skin and hair) in their blood – they should only be given Ruconest if their tests are negative.

Ruconest is given by slow injection into a vein lasting around five minutes. The dose depends on the patient’s body weight. One injection is usually enough to treat an attack, but a second injection may be given if the patient does not improve enough after the first one. A patient should not be given more than two injections within any 24-hour period.

How does it work?

The C1 esterase inhibitor protein is required to control the ‘complement’ and ‘contact’ systems, collections of proteins in the blood that fight against infection and cause inflammation. Patients with low levels of this protein have excessive activity these two systems, which leads to the symptoms of angioedema. The active substance in Ruconest, conestat alfa, is a copy of the C1 esterase inhibitor protein and works the same way as the natural human protein. When it is given during an angioedema attack, conestat alfa stops this excessive activity, helping to relieve the patient’s symptoms.

Conestat alfa is produced by ‘recombinant DNA technology’: it is extracted from the milk of rabbits that have been given genes that make them able to produce the human protein in their milk.

How has it been studied?

The effects of Ruconest were first tested in experimental models before being studied in humans.

Ruconest was studied in two main studies involving a total of 73 patients with hereditary angioedema caused by low levels of C1 esterase inhibitor protein. Most of the patients were adults. When an attack occurred, the patients were given one of two doses of Ruconest (50 or 100 units/kg) or placebo (a dummy treatment). Patients receiving the lower dose of Ruconest had the option of receiving a second dose up to four hours after the first. The main measure of effectiveness was how long it took for the symptoms to start to improve. Improvement was measured by the patients rating the severity of their symptoms on a scale from 0 to 100.

What benefits has it shown during the studies?

Ruconest was more effective than placebo at improving the symptoms of patients having an attack of angioedema. Patients receiving Ruconest at doses of 50 units/kg and 100 units/kg started to have improvements after one and two hours, respectively. Patients receiving placebo started to have improvements after four hours in one study and after over eight hours in the other.

Most patients were successfully treated with the 50-unit/kg dose, with only around 10% of the patients needing a second dose. This dose had a similar success rate to the higher dose of Ruconest.

What is the risk associated?

The most common side effect with Ruconest (seen in between 1 and 10 patients in 100) is headache. For the full list of all side effects reported with Ruconest, see the package leaflet.

Ruconest should not be used in people who may be hypersensitive (allergic) to conestat alfa or any of the other ingredients. It must not be used in patients with known or suspected allergy to rabbits.

Why has it been approved?

The CHMP decided that Ruconest’s benefits are greater than its risks and recommended that it be given marketing authorisation.

How has it been studied?

The company that makes Ruconest will ensure that healthcare professionals in all Member States who are expected to prescribe Ruconest are provided with an educational pack containing information on the proper use of the medicine and warnings about the risk of allergy. The company will also provide prescribers with an alert card for their patients.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Ruconest to Pharming Group N.V. on 28 October 2010. The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Ruconest, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 07-2010.

↑ back to table of contents ↑
 

Name

 

Ruconest 2100 U powder for solution for injection

 

Composition

 

One vial contains 2100 units of conestat alfa, corresponding to 2100 units per 14 ml after reconstitution, or a concentration of 150 units/ml.

Conestat alfa is the recombinant analogue of the human C1 esterase inhibitor (rhC1INH) produced by recombinant DNA technology in the milk of transgenic rabbits.

1 Unit of conestat alfa activity is defined as the equivalent of C1 esterase inhibiting activity present in 1 ml of pooled normal plasma.

For a full list of excipients, see section 6.1

 

Pharmaceutical Form

 

Powder for solution for injection.
White to off-white powder.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Bridion 100 mg/ml solution for .. 下一篇Dotarem 279.32 mg/ml iv 15 ml

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位